Immune thrombocytopenia (ITP) is an autoimmune disease characterized by a significant reduction in the number of circulating platelets which is frequently associated with bleeding. The total count of platelets in the body is finely regulated by the balance between platelet production and destruction. Although the pathogenesis of ITP is still not completely elucidated, it is largely recognized that the low platelet count observed in ITP patients is due to alterations of both mechanisms. An abnormal proliferation of autoreactive T cells leading to the breakdown of immune tolerance to platelet antigens is suggested to be responsible for the up-regulated proliferation of autoantibody producing B cells. Consequently, the immune response induces enhanced T cell-mediated cytotoxicity and antibody-mediated platelet destruction through phagocytosis, complement activation and apoptosis. An additional contribution to the pathophysiology of ITP is given by alterations of thrombopoiesis caused by platelet-reactive autoantibodies or cytotoxic T cells leading to impaired megakaryocyte differentiation and platelet production. All these processes involved in ITP pathophysiology account for the complexity and heterogeneity in the clinical manifestation and therapy responsiveness of this disorder. For this reason, a better understanding of the different underlying mechanisms in ITP is necessary to develop more efficient therapeutic treatments in the future. In this review, we will provide an update on the pathophysiology of ITP with a particular focus on the impact of impaired thrombopoiesis.
by humoral and cellular components, including primarily regulatory T and B cells (T regs and B regs). Functional alterations in these regulatory immune cells in ITP patients have been observed and are thought to contribute to ITP pathogenesis. For a long time, it was thought that the low platelet count is solely caused by enhanced destruction of platelets opsonized by anti-platelet antibodies.10–12 However, recent studies have shown that T cell cytotoxicity and impaired megakaryopoiesis are additional pathomechanisms in ITP. In this review, we will focus on the mechanisms leading to platelet destruction in ITP with a particular focus on current findings concerning alterations of thrombopoiesis.

Pathophysiology of ITP

T Cell in ITP; Dysfunction in Regulation and Effector Function

The loss of immunological tolerance to autoantigens expressed on patients’ own platelets is one of the critical issues in the pathophysiology of ITP. In this context, several studies reported T cell abnormalities with an imbalance in T helper (Th)1/Th2 ratio in ITP patients.13,14 T regs are another subgroup of immune cells that play a critical role in maintaining self-tolerance under physiological conditions. These cells suppress cell- and antibody-mediated autoimmune responses.15 Dysfunction of these cells is thought to be involved in pathogenesis of ITP.16,17 For instance, T regs were found to have reduced in vitro immunosuppressive activity.18 Moreover, an association was demonstrated between the severity of the disease (bleeding and thrombocytopenia) and the reduction of T regs.19 In fact, using a murine model, an increased severity of thrombocytopenia after depletion of CD8 T cell has been reported. While upon CD8 T regs re-transfusion correction in platelet counts was observed, indicating that CD8+ T regs are required to maintain the immunological tolerance.20 These findings were supported by an additional study performed using an animal model. Nishimoto et al showed that approximately 40% of T reg-deficient mice developed thrombocytopenia which lasted for up to 5 weeks. Thrombocytopenic mice produced immunoglobulin G (IgG) anti-platelet antibodies which enhanced by BAFF in ITP patients. Several studies showed higher serum levels of BAFF in untreated ITP patients, suggesting that these cells contribute to the autoantigen stimulation in ITP.30,31 The development and survival of B cells is regulated by the B cell activating factor of the TNF family (BAFF).32 Several studies showed higher serum levels of BAFF in untreated ITP patients, which were significantly reduced upon successful immunosuppressive therapy.33 Moreover, the up-regulation of THR7 in mice with ITP led to an enhancement in BAFF, with a subsequent decrease in platelet count.34,35 These findings indicate that survival of autoreactive B cells is enhanced by BAFF in ITP patients.

B Cell in ITP; Activated Humoral Autoimmune Response

It is generally accepted that ITP is associated with dysfunctions of B cells. The contribution of B cells to the pathogenesis of ITP is not restricted to the production of autoantibodies. Enhanced numbers of B cells have been observed in the red pulp spleen sections of ITP patients, suggesting that these cells contribute to the autoantigen stimulation in ITP.30,31 The development and survival of B cells is regulated by the B cell activating factor of the TNF family (BAFF).32 Several studies showed higher serum levels of BAFF in untreated ITP patients, which were significantly reduced upon successful immunosuppressive therapy.33 Moreover, the up-regulation of THR7 in mice with ITP led to an enhancement in BAFF, with a subsequent decrease in platelet count.34,35 These findings indicate that survival of autoreactive B cells is enhanced by BAFF in ITP patients.

Recently, several studies provided robust evidence concerning the involvement of B regs in chronic ITP patients.36,37 B regs (CD19 + CD24hiCD38hi) maintain peripheral tolerance by secretion of IL-10 leading to T regs recruitment and/or differentiation, and reduction of CD4+ T cell functionality.38,39 Notably, functional impairment of B regs was observed in non-splenectomized ITP patients with chronic ITP.36 The presence of autoantibodies produced by B cells in ITP is fully established.40 The first demonstration of the pathogenic effect of these antibodies took place in the early 1950s. Harrington and Hollingsworth demonstrated, for the first time, the existence of a ‘thrombocytopenic factor’ in the blood of ITP patients. They induced transient thrombocytopenia in healthy recipients who received 500 mL of whole blood from ITP patients. In these subjects a significant reduction in platelet count after 2 hours and a complete absence of platelets after 24 hours, with a gradual recovery after a few days,41 were observed. Years later, Shulman et al revealed that the
IIIa antibodies have been shown to have restricted usage. GPV demonstrated that autoantibodies in ITP are mainly directed to another recognize a short amino acid sequence (333–341) on GPIb/IX, which mainly was achieved with the introduction of immunocapture assays, in particular the monoclonal antibody-specific immobilization of platelet antigens (MAIPA). Using this assay, it has been demonstrated that autoantibodies in ITP are mainly directed against GPIb/IIa and GPIb/IX, but also GPIV, GPVI, GPIa/IIa and GPV. More recent research revealed that autoantibodies recognize several epitopes and require different conformations. Anti-GPIb/IIa antibodies, for example, frequently bind to cation-dependent conformational antigens on αIIbβ3, but not to another β3-containing integrin, αvβ3. These autoantibodies bind specifically to the β-propeller domain of αIIb, predominantly from the N-terminus to the W4:4–1 loop of the β-propeller domain. Interestingly, it was observed that in the presence of a single amino acid substitution in αIIb, the reactivity of some autoantibodies is completely inhibited, suggesting that target epitopes are extremely restricted to conformational epitopes. A similar effect was observed by He et al for antibodies targeting the GPIb/IX, which mainly recognize a short amino acid sequence (333–341) on GPIbα. Although most antibodies bind the GPIb component of the receptor complex GPIb/IX/V, little is known about relevant in the spleen. This process is mediated by low avidity Fc gamma receptors (FcgRs) IIA and FcgRIIIA which are linked to immune receptor tyrosine-based activation motifs (ITAMs) in the intracellular domain. Upon autoantibody binding, ITAMs are phosphorylated by the tyrosine kinase Syk, triggering the phagocytosis. Although all FcgRs are involved in activating the immune system, FcgRIIB is the only inhibitory Fc receptor. This is due to its immune receptor tyrosine-based inhibitory motif (ITIM) in the cytoplasmic tail which inhibits phagocytosis and the release of pro-inflammatory cytokines by macrophages and dendritic cells. In this context, the ratio between different FcgRs is critical to correctly regulate the immune response. In fact, patients responding to H. pylori eradication, a shift in monocyte FcgRs expression toward FcgRIIB has been reported. 

Table 1 Characteristics of glycoproteins (GPs) targeted by ITP autoantibodies

<table>
<thead>
<tr>
<th>Targets of AAbs</th>
<th>Copies/PLT</th>
<th>Ligand</th>
<th>Functions</th>
<th>Related disorders</th>
</tr>
</thead>
<tbody>
<tr>
<td>GPIb/IIa (αIIbβ3)</td>
<td>50,000–80,000</td>
<td>Fibrinogen</td>
<td>Platelet adhesion and aggregation</td>
<td>Glanzmann’s syndrome</td>
</tr>
<tr>
<td>GPIb/IX/V</td>
<td>~50,000</td>
<td>von Willebrand factor</td>
<td>Platelet adhesion and aggregation</td>
<td>Bernard–Soulier syndrome</td>
</tr>
<tr>
<td>GPIV</td>
<td>12,000–25,000</td>
<td>Collagen</td>
<td>Platelet activation and aggregation</td>
<td>–</td>
</tr>
<tr>
<td>GPIa/IIa</td>
<td>2,000–4,000</td>
<td>Collagen</td>
<td>Platelet activation and aggregation</td>
<td>–</td>
</tr>
<tr>
<td>αβ3</td>
<td>300–400</td>
<td>Vitronectin</td>
<td>Platelet adhesion and aggregation</td>
<td>–</td>
</tr>
</tbody>
</table>

Abbreviations: AAbs, autoantibodies; ITP, immune thrombocytopenia; PLT, platelet.
role of the FcγRIIB was also demonstrated in a study, using animal model, which showed that its presence on splenic macrophages is necessary for the protective effects of intravenous immunoglobulin (IVIG).

**Complement Activation**

Complement activation represents an additional important mechanism of platelet destruction. Several in vitro studies documented antibody-mediated complement fixation to platelets from ITP patients. GPIIb/IIIa and GPIb/IX are the major targets of autoantibodies with complement fixation capability. The biological significance of this observation was demonstrated using an established mouse model of ITP. The authors showed that platelet destruction by complement-fixing autoantibodies is significantly increased in the presence of complement. Taking these findings into account, novel therapies for ITP could target complement factors. For instance, eculizumab was shown to rescue thrombocytopenia in patients with anti-phospholipid syndrome by inhibition of the downstream components of complement.

**Fc-Independent Platelet Destruction**

The Fc-mediated platelet phagocytosis is a well-known mechanism in ITP pathogenesis. However, it has been estimated that 20% of ITP patients are refractory to the standard therapies that target the Fc receptor signalling, including splenectomy and IVIG. This indicates that, at least for this subgroup of patients, the antibody-mediated platelet destruction involves different pathways and site of clearance. Recent studies proposed two Fc-independent mechanisms. Using a murine model, Li and coworkers showed that ITP autoantibodies induce glycan modification of platelet surface GPs, which are recognized by Ashwell–Morell receptors, expressed on hepatocytes, leading to accelerated platelet clearance in the liver. In some patients, this may explain the ineffectiveness of splenectomy which represents the ultimate ITP therapeutic option for refractory subjects. Interestingly, 2 years later a retrospective study involving 61 ITP patients reported a correlation between platelets desialylation and a reduced response to first-line treatments corroborating the hypothesized Fc-independent mechanism. Another Fc-independent mechanism has been suggested by Quach et al who showed that non-responding ITP patients often produce autoantibodies targeting the ligand binding domain of GPIb/IX. This specific binding can activate GPIb/IX by platelet receptor-crosslinking, inducing unfolding of its mechanosensory domain and the consequent platelet destruction. However, it is currently unclear whether the unfolding of GPIb mechanosensory domain is the earlier event required for sialidase neuraminidase-1 translocation and platelet desialylation.

**Antibody-Mediated Platelet Apoptosis**

The platelet life cycle is regulated by the intrinsic apoptotic pathway similarly to nucleated cells. Considering this, the contribution of ITP autoantibodies in inducing platelet apoptosis was investigated by several groups using well-defined apoptosis markers such as depolarization of the mitochondrial transmembrane potential, Bcl-2 family protein expression, caspase-3 and 9 activation and phosphatidylserine (PS) exposure. One of the first studies performed using a mouse model for ITP showed that upon injection of anti-GPIIb antibodies, murine platelets displayed apoptotic features including destruction of the mitochondrial potential, Bcl-2 family protein expression, caspase-3 and 9 activation and PS exposure. In human ITP, platelet apoptosis has been reported in paediatric and adult patients with acute ITP which was ameliorated by immunoglobulin infusion. Interestingly, in a recent study apoptotic platelets were found in ITP patients expressing anti-GPIIb/IIIa and anti-GPIb autoantibodies but not in those carrying anti-GPIa/IIa autoantibodies. This suggests a possible preferential specificity of the autoantibodies in inducing platelets
apoptosis. Although, the exact mechanism of autoantibody-mediated platelet apoptosis is not yet completely clear, these findings suggest a relevant contribution of the apoptotic pathway in the ITP pathogenesis, opening novel horizons for deeper investigations.

**Physiological Thrombopoiesis**

In addition to the established mechanisms leading to platelet destruction, an equivalent role in the pathophysiology of ITP is played by antibody-mediated impaired platelet production. Megakaryopoiesis is a complex process that takes place in the bone marrow involving molecular and cellular changes leading to biogenesis of platelets. The primary activator and regulator of the process is the thrombopoietin (TPO) produced in the liver. TPO triggers the differentiation of haematopoietic stem cells (HSCs) into polyploid cells, known as megakaryocytes. Upon complete maturation, megakaryocytes develop proplatelet extensions through the endothelial cells of the vascular niche and finally release platelets into the blood stream (almost 10,000 platelets per megakaryocyte and a total of 100 million each day in healthy subjects). Bone marrow-derived mesenchymal stem cells (MSCs) are essential components in the haematopoietic microenvironment and provide support to megakaryopoiesis. They secrete a wide range of cytokines including interleukin 6 (IL-6), IL-10, IL-11, prostaglandins, stem cell factor (SCF) and leukaemia inhibitory factor which induce megakaryocyte biogenesis and maturation. These cells are capable of self-renewal and differentiation by which they maintain the correct balance between HSC and megakaryocyte differentiation in the bone marrow. Clearly, alterations in any stage of the megakaryopoiesis will affect platelet production (►Fig. 2).

**Thrombopoiesis in ITP**

The first observations of morphological alterations on megakaryocytes from ITP patients were reported in the 1940s. An increase of immature megakaryocytes, characterized by abnormalities in the ploidy state of the nucleus and cytoplasm, was observed in the bone marrow of ITP patients using light microscopy. Interestingly, after transfusion of ITP serum into

---

**Fig. 2** Altered thrombopoiesis in immune thrombocytopenia (ITP) patients. Upper panel: in physiological condition, thrombopoietin (TPO) induces the differentiation of haematopoietic stem cells (HSCs) into megakaryocyte progenitors (MK-P), immature MKs and finally into the mature MKs characterized by polyploid nucleus. These cells develop proplatelet extensions and release platelets (PLTs) in the blood stream. Mesenchymal stem cells (MSCs), residing in the bone marrow, support the entire process maintaining the balance between self-renewal and differentiation. Lower panel: during thrombopoiesis in ITP patients, different steps of the entire process are altered as shown in the figure (Adapted from Eto K. and Kunishima S., 2016, Blood.)
healthy subjects, the same alterations on megakaryocyte morphology were detected.\textsuperscript{84} This finding can be explained by the fact that GPIIb and GPIIIb/IIIa, the major targets of ITP autoantibodies, are expressed not only on the surface of platelets but also on megakaryocytes during their differentiation. The autoantibody binding results in suppression of megakaryocyte maturation and platelet formation.\textsuperscript{85,86} In fact, the antibody-mediated inhibition of platelet production was demonstrated by in vitro studies using HSCs that differentiated into megakaryocytes in the presence of ITP autoantibodies targeting GPIIb/IX and GPIIIb/IIIa. In those studies, impaired megakaryocyte maturation and decreased platelet formation were observed.\textsuperscript{87–89} In a more recent study, Zeng et al\textsuperscript{90} have investigated the impact of anti-αvβ3 autoantibody, which is expressed in chronic ITP patients, on megakaryocyte differentiation, survival, migratory and adhesive ability. In fact, the migration and adhesion of megakaryocytes, but a normal viability and proliferation of the cells, have been observed in the presence of anti-αvβ3 autoantibody. These findings suggest that anti-αvβ3 autoantibodies might have a selective inhibitory impact on megakaryocyte adhesion and migration during ITP pathogenesis. Furthermore, using a murine model the authors reported a lower count of megakaryocytes residing in the vascular niche in ITP mice. Interestingly, bone marrow biopsies of ITP patients, which express anti-αvβ3 antibody, have shown similar phenotype, corroborating the in vitro and in vivo findings. The results of this study indicate that anti-αvβ3 autoantibody might reduce megakaryocyte differentiation and platelet production through inhibition of the megakaryocyte’s migration ability.

Whereas conventional therapeutic approaches in ITP aimed mainly to reduce immune-mediated platelet destruction, newer treatments seek to increase thrombopoiesis and the consequent platelet production. Megakaryopoiesis suppression has been observed in ITP patients with autoantibodies targeting specifically the TPO receptor (TPO-R) c-Mpl.\textsuperscript{91} As a key activator and regulator of the platelet production process, the activation of c-Mpl receptor was one of the successful therapeutic targets investigated. In fact, platelet count increases have been addressed using TPO-R agonists such as romiplostim and eltrombopag.\textsuperscript{92,93} Clinical confirmation of the efficacy of these substances emerged from several randomized trials, performed during long-term treatment, which reported a 70 to 80% response in refractory ITP patients.\textsuperscript{94,95} Recently, Bal et al reported an additional therapeutic effect of TPO-R agonists showing increased proliferation, mobilization and differentiation of HSCs and early cell progenitors of all three haematopoietic lineages.\textsuperscript{96} Consequently, HSCs seem to be a promising tool for novel cell-based therapies in ITP.

Genetic factors with a potential association to ITP have been investigated extensively; however, it is still difficult to define a clear conclusion from the data currently available. Nevertheless, it has been reported that microRNAs (miRNAs), small non-coding RNA molecules that regulate gene expression by targeting messenger RNA (mRNA),\textsuperscript{97} change under pathological conditions. Interestingly, although the role of mRNA in ITP has not been completely elucidated,\textsuperscript{98,99} several miRNAs seem to have an impact on megakaryocyte differentiation. For instance, β1 tubulin R307H single-nucleotide polymorphism (SNP) was suggested to be a potential biomarker in ITP. It has been shown that 30% of ITP patients present SNP allele, and any difference observed in relation to SNP might influence a large number of patients. The relationship between changes in platelet physiology and changes in isotype of tubulin (as the main component of marginal band platelet) highlights the possible role of β1 tubulin in platelet activity.\textsuperscript{100,101}

**Megakaryocyte Apoptosis**

An interesting open question is the role of megakaryocyte apoptosis in the ITP pathophysiology. Controversial results were presented in several studies during the last few years. In fact, it has been reported that ITP plasma can reduce megakaryocyte apoptosis.\textsuperscript{102} In particular, after cultivation of HSCs from healthy umbilical cord blood with ITP plasma, a decreased percentage of apoptotic cells, reduced expression of tumor necrosis factor-related apoptosis inducing ligand (TRAIL) and increased expression of the anti-apoptotic protein Bcl-xL have been observed in the differentiated megakaryocytes.\textsuperscript{103} In contrast, an in vivo study by Houwerzijl et al showed that megakaryocytes undergo apoptosis in the presence of autoantibodies displaying nuclear fragmentation, chromatin condensation and activation of caspase 3 in biopsies of ITP patients, leading to phagocytosis of the polyploid cells by macrophages residing in the bone marrow.\textsuperscript{104}

Although the mechanisms of impaired megakaryopoiesis are not yet completely clear, it is well known that in bone marrow of ITP patients the number of megakaryocytes is normal or increased despite platelet production and count being reduced.\textsuperscript{105} In this context, the apoptotic pathways in megakaryocytes might represent an explanation. In fact, reduced apoptosis in megakaryocytes and their consequent long survival in the bone marrow without an effective megakaryopoiesis is a reasonable hypothesis. This theory is corroborated by a more recent study where megakaryocyte apoptosis was investigated in bone marrow samples of ITP patients.\textsuperscript{106} Vrbensky and coworkers have observed a decrease of megakaryocyte apoptosis in bone marrow biopsies of ITP subjects in comparison to healthy controls. In the same line, data from animal study showed that within 24 hours upon administration of different autoantibodies (anti-αdβh, anti-β3 or anti-GPIIb) all of them were able to develop thrombocytopenia in recipient mice. However, only two antibodies (anti-αdβh and anti-β3) have induced an alteration of the number of megakaryocytes in the bone marrow. This suggests that not all autoantibodies affect the megakaryocyte count and consequently a different mechanism may be the cause of megakaryocyte alterations during ITP.\textsuperscript{107}

**Defective Mesenchymal Stem Cells in ITP**

Emerging studies are suggesting a contribution of the defective MSCs in the mechanism leading to ITP pathogenesis. One of the most important properties of these cells is their immunosuppressive function, involving both adaptive and
innate immune responses. In fact, it was reported that MSCs could induce an immunosuppressive or tolerant phenotype in physiological conditions by altering the cytokine’s secretion functions of dendritic cells, effector T cells (Th1 and Th2) and natural killer cells. In contrast, functional impairment of MSCs was observed in different autoimmune disorders including rheumatoid arthritis, systemic lupus erythematosus and aplastic anaemia. Accordingly, these observations, several investigations have demonstrated that MSCs from ITP patients are characterized by increased number of apoptotic cells and reduced capacity to inhibit the proliferation of activated T cells. Given these findings, defective MSCs are currently being explored as a potential target in the treatment of ITP. A few years ago it was reported that platelet-derived growth factor (PDGF-BB) has a protective effect on MSCs. PDGF-BB was found to act against apoptosis, senescence and immunomodulatory dysfunctions. These observations were corroborated by Tao et al who demonstrated that transplantation of healthy MSCs can rescue the functional immune phenotype in a murine model of ITP. The administration of MSCs induced a significantly decreased level of Tregs and an increase in platelet count in ITP mice. These observations were further supported by a recent clinical study exhibiting a similar experimental setting that involved four patients with chronic refractory ITP. A complete remission was achieved in three patients within 12 months and for one patient after 24 months, without additional immunosuppressive drugs. Interestingly, during follow-up analysis no severe side effects were observed, suggesting that MSC transplantation seems to be a safe and efficient cell-based therapeutic approach to treat refractory ITP.

Conclusion

ITP is a complex and multifactorial disease. In fact, the clinical manifestations as well as patients’ response to different treatments are very heterogeneous suggesting that ITP is a group of disorders sharing common characteristics, namely loss of immune tolerance toward platelet (and megakaryocyte) antigens and dysfunctional primary haemostasis. Recent studies provided significant insight into the pathophysiology of ITP including identification of the role of antigen-presenting cells, T and B cells, and their interactions. Of most importance was the discovery that the abnormal functions of B regs and T regs, which are supposed to maintain self-tolerance, are involved in modulating ITP pathogenesis. The immunological consequence of the activated B and T cell-mediated immune response is the proliferation of platelet-specific plasma and cytotoxic cells, respectively. While the latter are responsible for a direct destruction of platelet as well as megakaryocyte in ITP, IgG autoantibodies generally directed at the most abundant platelet surface GPs (GPIIb/IIa and GPIb/IX/V) can induce thrombocytopenia in ITP by several Fc-domain dependent mechanisms including platelet phagocytosis, complement activation, apoptosis, cell lysis and inhibition of proplatelet production. Additionally, recent data suggest that surface expression of sialic acid can be modified by autoantibodies leading to platelet clearance via Ashwell–Morell receptor (AMR) system in the liver in an Fc-independent manner. Of note, some patients show a decrease in autoantibody concentration after treatment with steroids but no significant improvement in platelet count (personal observation). Since only platelets are used in antibody tests, it could be possible that autoantibodies with higher avidity to megakaryocytes are still circulating but not detectable using standard assays. These autoantibodies with a preferential binding to megakaryocytes could induce thrombocytopenia via inhibition of thrombopoiesis. Although this hypothesis is speculative, future investigations could help understand the heterogeneity that is frequently observed in the responsiveness of ITP patients to different treatments. Future studies should also aim to investigate the increased platelet mass due to various therapies, and its role in presenting platelet autoantigens to T cells and potential effects on activating and suppressing T regs, which may elucidate novel pathomechanisms. Taking the heterogeneity of ITP into consideration, improving our knowledge of the pathogenesis of ITP is an essential cornerstone for identifying effective diagnostic tests and efficient therapeutic approaches for this clinically relevant form of acquired thrombocytopenia.

Author Contributions

Irene Marini did the literature search and wrote the sections on alterations of megakaryopoiesis and thrombopoiesis. Tamam Bakchoul contributed to the subsections on the antibody-mediated platelet clearance. Both authors approved the final version of the manuscript.

Conflict of Interest

I.M. has no conflict of interests.

T.B. reports receiving honoraria for a scientific talk from Aspen Germany, CSL Behring and Stago gGmbH German, and research grants from the German Society of Research, the German Society for Transfusion Medicine and German Red Cross.

Acknowledgment

The authors thank Stephen Bosher for editing the manuscript as a native English speaker.

References

data from the Intercontinental Cooperative ITP Study Group Registry II participants. Pediatr Blood Cancer 2018;65(1)


8 Takahashi T, Yujiri T, Tanizawa Y. Helicobacter pylori and chronic ITP: the discrepancy in the clinical responses to eradication therapy might be due to differences in the bacterial strains. Blood 2004;104(02):594


19 Ma D, Zhu X, Zhao P, et al. Profile of Th17 cytokines (IL-17, TGFbeta, IL-6) and Th1 cytokine (IFN-gamma) in patients with immune thrombocytopenic purpura. Ann Hematol 2008;87(11):899–904

20 Ma L, Simpson E, Li J, et al. CD8+ T cells are predominantly protective and required for effective steroid therapy in murine models of immune thrombocytopenia. Blood 2015;126(02):247–256


38 Blair PA, Noreña LF, Flores-Borja F, et al. CD19(+)CD24(+)CD38(+) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic lupus erythematosus patients. Immunity 2010;32(01):129–140


Pathophysiology of Immune Thrombocytopenia Marini, Bakhoul 235


Frelinger AL III, Grace RF, Gerrits AJ, Carmichael SL, Forde EE, Michelson AD. Platelet function in ITP: independent of platelet count, is consistent over time and is associated with both current and subsequent bleeding severity. Thromb Haemost 2018;113(01):143–151


Hämostaseologie Vol. 39 No. 3/2019

Sheng GY, Huang XL, Bai ST. Expression levels of CXCR4 on


Chang M, Nakagawa PA, Williams SA, et al. Immune thrombocyto-


Iraqi M, Perdomo J, Yan F, Choi PY, Chong BH. Immune thrombocyto-
penia: antiplatelet autoantibodies inhibit proplatelet formation by megakaryocytes and impair platelet production in vitro. Haematologica 2015;100(05):623–632


Kuter DJ. Biology and chemistry of thrombopoietic agents. Semin Hema-


Bal G, Fabian D, Maia D, Ringel F, Salama A. Effect of thrombo-
poeitin receptor agonists on leukocyte and haematopoietic stem and progenitor cells in the peripheral blood of patients with immune thrombocytopenic purpura. Ann Hematol 2017;96 (12): 2045–2056

Sheng GY, Huang XL, Bai ST. Expression levels of CXCR4 on


Bay A, Coskun E, Oztuzcu S, Ergun S, Yilmaz F, Aktekin E. Plasma microRNA profiling of pediatric patients with immune thrombocyto-


Yang L, Wang L, Zhao CH, et al. Contributions of TRAIL-mediated megakaryocyte apoptosis to impaired megakaryocyte and pla-

Radley JM, Haller CJ. Fate of senescent megakaryocytes in the bone marrow. Br J Haematol 1983;53(02):277–287

Houwerzijl EJ, Blom NR, van der Want JJ, et al. Ultrastructural study shows morphologic features of apoptosis and para-apop-
tosis in megakaryocytes from patients with idiopathic thrombocyto-


Kim N, Im KI, Lim JY, et al. Mesenchymal stem cells for the treatment and prevention of graft-versus-host disease: experi-

Mohanty ST, Kottam I, Gambardella A, et al. Alterations in the self-


Madonna R, Petrov L, Teberino MA, et al. Transplantation of adipose tissue mesenchymal cells conjugated with VEGF-releasing microrobrines promotes repair in murine myocardial infarc-

Immunol 2018;88(01):e12678


development and prevention of graft-versus-host disease: experi-

Basciano PA, Bussel J, Hafeez Z, Christos PJ, Giannakakou P. The

Arnold DM, Nazi I, Kelton JC. New treatments for idiopathic

Immune Thrombocytopenia Marini, Bakchoul